# Ted M Dawson

List of Publications by Year
in descending order



| 401 | 77,826 | 498 132 | 616 266 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 472 | 472 | 472 | 73100 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | CYFIP1 Dosages Exhibit Divergent Behavioral Impact via Diametric Regulation of NMDA Receptor Complex Translation in Mouse Models of Psychiatric Disorders. Biological Psychiatry, 2022, 92, 815-826. | 0.7 | 8 |
| 2 | ADPâ€ribosyltransferases, an update on function and nomenclature. FEBS Journal, 2022, 289, 7399-7410. | 2.2 | 150 |
| 3 | Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762. | 3.7 | 17 |
| 4 | Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological Î±-synuclein. Cell Reports, 2022, 38, 110358. | 2.9 | 18 |
| 5 | Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver. IScience, 2022, 25, 103996. | 1.9 | 19 |
| 6 | Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinsonâ€™s disease. Science Advances, 2022, 8, eabh1824. | 4.7 | 12 |
| 7 | STING mediates neurodegeneration and neuroinflammation in nigrostriatal Î±-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2118819119. | 3.3 | 64 |
| 8 | A high-affinity cocaine binding site associated with the brain acid soluble protein 1. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200545119. | 3.3 | 2 |
| 9 | Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease. Movement Disorders, 2022, 37, 1454-1464. | 2.2 | 13 |
| 10 | PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinsonâ€™s disease. Cell, 2022, 185, 1943-1959.e21. | 13.5 | 36 |
| 11 | Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinsonâ€™s disease. Neuron, 2022, 110, 2422-2437.e9. | 3.8 | 64 |
| 12 | Nanozyme scavenging ROS for prevention of pathologic Î±-synuclein transmission in Parkinsonâ€™s disease. Nano Today, 2021, 36, 101027. | 6.2 | 78 |
| 13 | Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2021, 29, 958-968. | 0.6 | 17 |
| 14 | Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303. | 9.4 | 198 |
| 15 | Lymphocyte Activation Gene 3 (Lag3) Contributes to Î±-Synucleinopathy in Î±-Synuclein Transgenic Mice. Frontiers in Cellular Neuroscience, 2021, 15, 656426. | 1.8 | 29 |
| 16 | Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. JAMA Neurology, 2021, 78, 312. | 4.5 | 83 |
| 17 | The cell biology of Parkinsonâ€™s disease. Journal of Cell Biology, 2021, 220, . | 2.3 | 77 |
| 18 | AIF3 splicing switch triggers neurodegeneration. Molecular Neurodegeneration, 2021, 16, 25. | 4.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 78. | 2.4 | 82 |
| 20 | Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 469-480. | 0.8 | 10 |
| 21 | Targeting Parthanatos in Ischemic Stroke. Frontiers in Neurology, 2021, 12, 662034. | 1.1 | 28 |
| 22 | Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons. STAR Protocols, 2021, 2, 100405. | 0.5 | 7 |
| 23 | Mechanistic basis for receptor-mediated pathological Î±-synuclein fibril cell-to-cell transmission in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 59 |
| 24 | Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. ELife, 2021, 10, . | 2.8 | 15 |
| 25 | Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in Î±-Synuclein-Based Mouse Models of Parkinsonâ€™s Disease. Journal of Proteome Research, 2021, 20, 3428-3443. | 1.8 | 21 |
| 26 | Neurodegenerative disorders and gut-brain interactions. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 55 |
| 27 | Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 1834-1848. | 2.1 | 11 |
| 28 | PARIS farnesylation prevents neurodegeneration in models of Parkinsonâ€™s disease. Science Translational Medicine, 2021, 13, . | 5.8 | 30 |
| 29 | Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141. | 1.1 | 9 |
| 30 | Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. Brain, 2021, 144, 3674-3691. | 3.7 | 13 |
| 31 | LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8. Cells, 2021, 10, 203. | 1.8 | 1 |
| 32 | USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing. Nucleic Acids Research, 2021, 49, 11083-11102. | 6.5 | 12 |
| 33 | Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. Pharmacological Reviews, 2021, 73, 1204-1268. | 7.1 | 11 |
| 34 | TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinsonâ€™s disease. Neuron, 2021, 109, 3758-3774.e11. | 3.8 | 26 |
| 35 | Waiting for PARISâ€"A Biological Target in Search of a Drug. Journal of Parkinson's Disease, 2021, , 1-9. | 1.5 | 2 |
| 36 | Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-Î³ associated gene regulation. Scientific Reports, 2021, 11, 21500. | 1.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. ENeuro, 2021, 8, ENEURO.0310-21.2021. | 0.9 | 6 |
| 38 | Recent advances in preventing neurodegenerative diseases. Faculty Reviews, 2021, 10, 81. | 1.7 | 4 |
| 39 | Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248. | 3.7 | 149 |
| 40 | Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. Cell Stem Cell, 2020, 27, 633-645.e7. | 5.2 | 38 |
| 41 | Meta-Analysis of the Alzheimerâ€™s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908. | 2.9 | 199 |
| 42 | Determinants of seeding and spreading of Î±-synuclein pathology in the brain. Science Advances, 2020, 6, . | 4.7 | 61 |
| 43 | Microglia and astrocyte dysfunction in parkinson's disease. Neurobiology of Disease, 2020, 144, 105028. | 2.1 | 177 |
| 44 | Molecular Mediation of Prion-like Î±-Synuclein Fibrillation from Toxic PFFs to Nontoxic Species. ACS Applied Bio Materials, 2020, 3, 6096-6102. | 2.3 | 8 |
| 45 | Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. Stem Cell Reports, 2020, 15, 629-645. | 2.3 | 48 |
| 46 | AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF. Cell Reports, 2020, 33, 108329. | 2.9 | 12 |
| 47 | Development of a novel method for the quantification of tyrosine 39 phosphorylated Î±- and Î²-synuclein in human cerebrospinal fluid. Clinical Proteomics, 2020, 17, 13. | 1.1 | 10 |
| 48 | Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. International Review of Cell and Molecular Biology, 2020, 353, 1-29. | 1.6 | 63 |
| 49 | PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Molecular Neurodegeneration, 2020, 15, 17. | 4.4 | 58 |
| 50 | PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, 20. | 4.4 | 264 |
| 51 | Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke. PLoS ONE, 2020, 15, e0231978. | 1.1 | 11 |
| 52 | NLRP3 inflammasome activation in dopamine neurons contributes to neurodegeneration in Parkinsonâ€™s Disease. FASEB Journal, 2020, 34, 1-1. | 0.2 | 6 |
| 53 | Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain. Bio-protocol, 2020, 10, e3746. | 0.2 | 2 |
| 54 | Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2019, 7, 125. | 2.4 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | SQSTM1/p62 promotes mitochondrial ubiquitination independently of PINK1 and PRKN/parkin in mitophagy. Autophagy, 2019, 15, 2012-2018. | 4.3 | 93 |
| 56 | Transneuronal Propagation of Pathologic Î±-Synuclein from the Gut to the Brain Models Parkinsonâ€™s Disease. Neuron, 2019, 103, 627-641.e7. | 3.8 | 830 |
| 57 | Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinsonâ€™s disease. Brain, 2019, 142, 2380-2401. | 3.7 | 46 |
| 58 | The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. Movement Disorders, 2019, 34, 959-969. | 2.2 | 68 |
| 59 | Fyn kinase regulates misfolded Î±-synuclein uptake and NLRP3 inflammasome activation in microglia. Journal of Experimental Medicine, 2019, 216, 1411-1430. | 4.2 | 169 |
| 60 | Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501. | 2.1 | 29 |
| 61 | Assessment of APOE in atypical parkinsonism syndromes. Neurobiology of Disease, 2019, 127, 142-146. | 2.1 | 21 |
| 62 | Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities. ENeuro, 2019, 6, ENEURO.0148-19.2019. | 0.9 | 16 |
| 63 | Promising disease-modifying therapies for Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, . | 5.8 | 46 |
| 64 | Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiology of Aging, 2019, 76, 214.e1-214.e9. | 1.5 | 25 |
| 65 | Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. Stem Cells Translational Medicine, 2019, 8, 112-123. | 1.6 | 39 |
| 66 | A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10. | 1.5 | 13 |
| 67 | The AAAâ€‰+â€‰ATPase Thorase is neuroprotective against ischemic injury. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1836-1848. | 2.4 | 10 |
| 68 | Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 29-36. | 1.1 | 94 |
| 69 | Nitric Oxide Signaling in Neurodegeneration and Cell Death. Advances in Pharmacology, 2018, 82, 57-83. | 1.2 | 65 |
| 70 | DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders. Translational Psychiatry, 2018, 8, 76. | 2.4 | 34 |
| 71 | A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. Brain, 2018, 141, 651-661. | 3.7 | 52 |
| 72 | Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1635-1640. | 3.3 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Pathological Endogenous Î±-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. Stem Cell Reports, 2018, 10, 356-365. | 2.3 | 61 |
| 74 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541. | 5.0 | 4,036 |
| 75 | GBA1 deficiency negatively affects physiological Î±-synuclein tetramers and related multimers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 798-803. | 3.3 | 139 |
| 76 | Opportunities for the repurposing of PARP inhibitors for the therapy of nonâ€oncological diseases. British Journal of Pharmacology, 2018, 175, 192-222. | 2.7 | 160 |
| 77 | Domainâ€specific cognitive impairment in nonâ€demented Parkinson's disease psychosis. International Journal of Geriatric Psychiatry, 2018, 33, e131-e139. | 1.3 | 9 |
| 78 | Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 47, 50-56. | 1.1 | 14 |
| 79 | Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Movement Disorders Clinical Practice, 2018, 5, 31-38. | 0.8 | 9 |
| 80 | Animal models of neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1370-1379. | 7.1 | 358 |
| 81 | Poly(ADP-ribose) drives pathologic Î±-synuclein neurodegeneration in Parkinsonâ€™s disease. Science, 2018, 362, . | 6.0 | 317 |
| 82 | The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. Juntendo Medical Journal, 2018, 64, 17-30. | 0.1 | 0 |
| 83 | Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 53, 108-109. | 1.1 | 1 |
| 84 | Reply: ATAD1 encephalopathy and stiff baby syndrome: a recognizable clinical presentation. Brain, 2018, 141, e50-e50. | 3.7 | 1 |
| 85 | Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease. Cell Metabolism, 2018, 28, 588-604.e5. | 7.2 | 180 |
| 86 | Î±-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Molecular Neurodegeneration, 2018, 13, 1. | 4.4 | 143 |
| 87 | Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Molecular Neurodegeneration, 2018, 13, 8. | 4.4 | 87 |
| 88 | Finding useful biomarkers for Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, . | 5.8 | 125 |
| 89 | Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism and Related Disorders, 2018, 55, 8-14. | 1.1 | 37 |
| 90 | Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinsonâ€™s disease. Nature Medicine, 2018, 24, 931-938. | 15.2 | 712 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 2017, 541, 481-487. | 13.7 | 4,977 |
| 92 | Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annual Review of Pharmacology and Toxicology, 2017, 57, 437-454. | 4.2 | 120 |
| 93 | PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Reports, 2017, 18, 918-932. | 2.9 | 141 |
| 94 | Precision therapy for a new disorder of AMPA receptor recycling due to mutations in <i>ATAD1</i>. Neurology: Genetics, 2017, 3, e130. | 0.9 | 40 |
| 95 | The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Molecular Neurodegeneration, 2017, 12, 32. | 4.4 | 62 |
| 96 | Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes. Experimental Neurology, 2017, 298, 191-201. | 2.0 | 55 |
| 97 | Prediction of cognition in Parkinson's disease with a clinicalâ€"genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629. | 4.9 | 131 |
| 98 | T cells from patients with Parkinsonâ€™s disease recognize Î±-synuclein peptides. Nature, 2017, 546, 656-661. | 13.7 | 618 |
| 99 | Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e33-e33. | 3.7 | 2 |
| 100 | Models of LRRK2-Associated Parkinsonâ€™s Disease. Advances in Neurobiology, 2017, 14, 163-191. | 1.3 | 50 |
| 101 | Activation mechanisms of the E3 ubiquitin ligase parkin. Biochemical Journal, 2017, 474, 3075-3086. | 1.7 | 47 |
| 102 | Toward the human cellular microRNAome. Genome Research, 2017, 27, 1769-1781. | 2.4 | 142 |
| 103 | Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. Science Translational Medicine, 2017, 9, . | 5.8 | 20 |
| 104 | Two approaches reveal a new paradigm of â€˜switchable or genetics-influenced allele-specific DNA methylationâ€™ with potential in human disease. Cell Discovery, 2017, 3, 17038. | 3.1 | 25 |
| 105 | Cell Death Mechanisms of Neurodegeneration. Advances in Neurobiology, 2017, 15, 403-425. | 1.3 | 90 |
| 106 | Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine, 2017, 11, 451-473. | 0.6 | 49 |
| 107 | Heterozygous PINK1 p.G411S increases risk of Parkinsonâ€™s disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117. | 3.7 | 116 |
| 108 | Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1982-1993. | 2.4 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | c-Abl and Parkinsonâ€™s Disease: Mechanisms and Therapeutic Potential. Journal of Parkinson's Disease, 2017, 7, 589-601. | 1.5 | 67 |
| 110 | Overexpression of Parkinsonâ€™s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and Î±-Synuclein Pathology. ENeuro, 2017, 4, ENEURO.0004-17.2017. | 0.9 | 31 |
| 111 | The NINDS Parkinson's disease biomarkers program. Movement Disorders, 2016, 31, 915-923. | 2.2 | 83 |
| 112 | LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. Journal of Chemical Neuroanatomy, 2016, 76, 90-97. | 1.0 | 36 |
| 113 | Pathological Î±-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 2016, 353, . | 6.0 | 521 |
| 114 | Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. Parkinsonism and Related Disorders, 2016, 33, 107-114. | 1.1 | 21 |
| 115 | Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 33, 102-106. | 1.1 | 8 |
| 116 | A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science, 2016, 354, . | 6.0 | 266 |
| 117 | LRRK2 pathobiology in Parkinson's disease â€" virtual inclusion. Journal of Neurochemistry, 2016, 139, 75-76. | 2.1 | 5 |
| 118 | Association of<i>GBA</i>Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217. | 4.5 | 185 |
| 119 | Ubiquitination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nature Communications, 2016, 7, 11792. | 5.8 | 56 |
| 120 | Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. Science Translational Medicine, 2016, 8, 333ra48. | 5.8 | 66 |
| 121 | <b><i>C9orf72</i></b> Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. Neurodegenerative Diseases, 2016, 16, 370-372. | 0.8 | 8 |
| 122 | Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiology of Disease, 2016, 94, 55-62. | 2.1 | 55 |
| 123 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222. | 4.3 | 4,701 |
| 124 | <i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 95-102. | 2.2 | 158 |
| 125 | Activation of tyrosine kinase c-Abl contributes to Î±-synucleinâ€"induced neurodegeneration. Journal of Clinical Investigation, 2016, 126, 2970-2988. | 3.9 | 133 |
| 126 | Adult Conditional Knockout of PGC-1Î± Leads to Loss of Dopamine Neurons. ENeuro, 2016, 3, ENEURO.0183-16.2016. | 0.9 | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | High-Content Genome-Wide RNAi Screen Reveals<i>CCR3</i>as a Key Mediator of Neuronal Cell Death. ENeuro, 2016, 3, ENEURO.0185-16.2016. | 0.9 | 15 |
| 128 | (Pathoâ€)physiological relevance of <scp>PINK</scp> 1â€dependent ubiquitin phosphorylation. EMBO Reports, 2015, 16, 1114-1130. | 2.0 | 147 |
| 129 | Lysosomal Enzyme Glucocerebrosidase Protects against AÎ²1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854. | 1.1 | 12 |
| 130 | <i>PARK10</i> is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980. | 1.5 | 48 |
| 131 | Cognitive profile of <i>LRRK2</i>â€related Parkinson's disease. Movement Disorders, 2015, 30, 728-733. | 2.2 | 64 |
| 132 | TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinsonâ€™s disease via CNTF. Brain, 2015, 138, 3610-3622. | 3.7 | 95 |
| 133 | Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11696-11701. | 3.3 | 207 |
| 134 | Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Human Molecular Genetics, 2014, 23, 2055-2077. | 1.4 | 113 |
| 135 | Abberant protein synthesis in G2019S LRRK2<i>Drosophila</i>Parkinson disease-related phenotypes. Fly, 2014, 8, 165-169. | 0.9 | 19 |
| 136 | <scp>M</scp>sp1/<scp>ATAD</scp>1 maintains mitochondrial function by facilitating the degradation of mislocalized tailâ€anchored proteins. EMBO Journal, 2014, 33, 1548-1564. | 3.5 | 172 |
| 137 | Protein Microarray Characterization of the S-Nitrosoproteome. Molecular and Cellular Proteomics, 2014, 13, 63-72. | 2.5 | 56 |
| 138 | LRRK2 pathobiology in Parkinson's disease. Journal of Neurochemistry, 2014, 131, 554-565. | 2.1 | 131 |
| 139 | Proneural Transcription Factor Atoh1 Drives Highly Efficient Differentiation of Human Pluripotent Stem Cells Into Dopaminergic Neurons. Stem Cells Translational Medicine, 2014, 3, 888-898. | 1.6 | 35 |
| 140 | A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543. | 4.5 | 312 |
| 141 | Motor Neuron Death in ALS: Programmed by Astrocytes?. Neuron, 2014, 81, 961-963. | 3.8 | 23 |
| 142 | Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinsonâ€™s Disease. Cell, 2014, 157, 472-485. | 13.5 | 239 |
| 143 | Parkin and PINK1: much more than mitophagy. Trends in Neurosciences, 2014, 37, 315-324. | 4.2 | 309 |
| 144 | Parkin Plays a Role in Sporadic Parkinson's Disease. Neurodegenerative Diseases, 2014, 13, 69-71. | 0.8 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Early-onset Parkinson's disease due to PINK1 p.Q456X mutation â€“ Clinical and functional study. Parkinsonism and Related Disorders, 2014, 20, 1274-1278. | 1.1 | 41 |
| 146 | Parkinâ€independent mitophagy requires <scp>D</scp>rp1 and maintains the integrity of mammalian heart and brain. EMBO Journal, 2014, 33, 2798-2813. | 3.5 | 361 |
| 147 | Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10209-10214. | 3.3 | 253 |
| 148 | Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinsonâ€™s-like movement disorder. Nature Communications, 2014, 5, 4930. | 5.8 | 118 |
| 149 | Ganglioside Regulation of AMPA Receptor Trafficking. Journal of Neuroscience, 2014, 34, 13246-13258. | 1.7 | 45 |
| 150 | MiR-223 regulates the differentiation of immature neurons. Molecular and Cellular Therapies, 2014, 2, 18. | 0.2 | 24 |
| 151 | Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiology of Disease, 2014, 71, 345-358. | 2.1 | 59 |
| 152 | Parthanatos: mitochondrialâ€linked mechanisms and therapeutic opportunities. British Journal of Pharmacology, 2014, 171, 2000-2016. | 2.7 | 432 |
| 153 | Botch Is a Î³-Glutamyl Cyclotransferase that Deglycinates and Antagonizes Notch. Cell Reports, 2014, 7, 681-688. | 2.9 | 29 |
| 154 | Absence of <i>C9ORF72</i> expanded or intermediate repeats in autopsyâ€confirmed Parkinson's disease. Movement Disorders, 2014, 29, 827-830. | 2.2 | 24 |
| 155 | The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Scientific Reports, 2014, 4, 4874. | 1.6 | 188 |
| 156 | Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nature Neuroscience, 2013, 16, 1392-1400. | 7.1 | 182 |
| 157 | Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Molecular Aspects of Medicine, 2013, 34, 1066-1087. | 2.7 | 141 |
| 158 | Usp16: key controller of stem cells in Down syndrome. EMBO Journal, 2013, 32, 2788-2789. | 3.5 | 6 |
| 159 | New synaptic and molecular targets for neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 51-60. | 2.2 | 34 |
| 160 | Sulfhydration mediates neuroprotective actions of parkin. Nature Communications, 2013, 4, 1626. | 5.8 | 265 |
| 161 | The interplay of microRNA and neuronal activity in health and disease. Frontiers in Cellular Neuroscience, 2013, 7, 136. | 1.8 | 50 |
| 162 | LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization. PLoS ONE, 2013, 8, e77198. | 1.1 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Linked Clinical Trials â€“ The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments. Journal of Parkinson's Disease, 2013, 3, 231-239. | 1.5 | 35 |
| 164 | Ironing out tau's role in parkinsonism. Nature Medicine, 2012, 18, 197-198. | 15.2 | 13 |
| 165 | ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2. Journal of Neuroscience, 2012, 32, 3877-3886. | 1.7 | 92 |
| 166 | Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Human Molecular Genetics, 2012, 21, 163-174. | 1.4 | 34 |
| 167 | Animal Models of Parkinson's Disease: Vertebrate Genetics. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009324-a009324. | 2.9 | 99 |
| 168 | Neurodegenerative phenotypes in an A53T Â-synuclein transgenic mouse model are independent of LRRK2. Human Molecular Genetics, 2012, 21, 2420-2431. | 1.4 | 84 |
| 169 | Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy. Journal of Neuroscience, 2012, 32, 16503-16509. | 1.7 | 124 |
| 170 | LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochemical Society Transactions, 2012, 40, 1074-1079. | 1.6 | 21 |
| 171 | MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18962-18967. | 3.3 | 245 |
| 172 | Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends in Pharmacological Sciences, 2012, 33, 365-373. | 4.0 | 69 |
| 173 | Botch Promotes Neurogenesis by Antagonizing Notch. Developmental Cell, 2012, 22, 707-720. | 3.1 | 54 |
| 174 | Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i>. Annals of Neurology, 2012, 71, 370-384. | 2.8 | 264 |
| 175 | Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90. | 5.8 | 444 |
| 176 | Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinsonâ€™s Disease-Related Toxicity in Human Neurons. ACS Chemical Biology, 2011, 6, 1021-1028. | 1.6 | 131 |
| 177 | PARIS (ZNF746) Repression of PGC-1Î± Contributes to Neurodegeneration in Parkinson's Disease. Cell, 2011, 144, 689-702. | 13.5 | 796 |
| 178 | The AAA+ ATPase Thorase Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior. Cell, 2011, 145, 284-299. | 13.5 | 88 |
| 179 | Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1â€“Dependent Cell Death (Parthanatos). Science Signaling, 2011, 4, ra20. | 1.6 | 360 |
| 180 | MicroRNAs in Parkinson's disease. Journal of Chemical Neuroanatomy, 2011, 42, 127-130. | 1.0 | 142 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE, 2011, 6, e18568. | 1.1 | 338 |
| 182 | Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nature Medicine, 2011, 17, 692-699. | 15.2 | 190 |
| 183 | Recent Advances in the Genetics of Parkinson's Disease. Annual Review of Genomics and Human Genetics, 2011, 12, 301-325. | 2.5 | 355 |
| 184 | A perfect â€œMatchâ€•for in vitro human disease modeling and autologous cell-based transplantation therapy: Generating genetically identical Parkinson's disease and control pluripotent stem cells by precise gene targeting. Movement Disorders, 2011, 26, 1804-1804. | 2.2 | 0 |
| 185 | Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14103-14108. | 3.3 | 205 |
| 186 | A Lysosomal Lair for a Pathogenic Protein Pair. Science Translational Medicine, 2011, 3, 91ps28. | 5.8 | 11 |
| 187 | Enhanced Autophagy from Chronic Toxicity of Iron and Mutant A53T Î±-Synuclein. Journal of Biological Chemistry, 2011, 286, 33380-33389. | 1.6 | 82 |
| 188 | Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 2011, 20, 3933-3942. | 1.4 | 120 |
| 189 | Resistance to MPTP-Neurotoxicity in Î±-Synuclein Knockout Mice Is Complemented by Human Î±-Synuclein and Associated with Increased Î²-Synuclein and Akt Activation. PLoS ONE, 2011, 6, e16706. | 1.1 | 57 |
| 190 | Neuronal Activity Regulates Hippocampal miRNA Expression. PLoS ONE, 2011, 6, e25068. | 1.1 | 48 |
| 191 | The role of parkin in familial and sporadic Parkinson's disease. Movement Disorders, 2010, 25, S32-9. | 2.2 | 309 |
| 192 | Contributions of poly(ADPâ€ribose) polymeraseâ€1 and â€2 to nuclear translocation of apoptosisâ€inducing factor and injury from focal cerebral ischemia. Journal of Neurochemistry, 2010, 113, 1012-1022. | 2.1 | 51 |
| 193 | Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000. | 15.2 | 342 |
| 194 | NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. Journal of Clinical Investigation, 2010, 120, 2446-2456. | 3.9 | 42 |
| 195 | Synphilin-1 attenuates neuronal degeneration in the A53T Â-synuclein transgenic mouse model. Human Molecular Genetics, 2010, 19, 2087-2098. | 1.4 | 65 |
| 196 | Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2. Journal of Biological Chemistry, 2010, 285, 29569-29576. | 1.6 | 48 |
| 197 | Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16691-16696. | 3.3 | 241 |
| 198 | PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 378-383. | 3.3 | 1,415 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R215-R221. | 0.9 | 18 |
| 200 | GTPase Activity Plays a Key Role in the Pathobiology of LRRK2. PLoS Genetics, 2010, 6, e1000902. | 1.5 | 177 |
| 201 | The impact of genetic research on our understanding of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 183, 21-41. | 0.9 | 26 |
| 202 | Genetic Animal Models of Parkinson's Disease. Neuron, 2010, 66, 646-661. | 3.8 | 714 |
| 203 | Functional Identification of Neuroprotective Molecules. PLoS ONE, 2010, 5, e15008. | 1.1 | 31 |
| 204 | S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4900-4905. | 3.3 | 141 |
| 205 | CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2897-2902. | 3.3 | 195 |
| 206 | Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila. Journal of Neuroscience, 2009, 29, 11257-11262. | 1.7 | 193 |
| 207 | Outer Mitochondrial Membrane Localization of Apoptosis-Inducing Factor: Mechanistic Implications for Release. ASN Neuro, 2009, 1, AN20090046. | 1.5 | 69 |
| 208 | Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radical Biology and Medicine, 2009, 47, 1049-1056. | 1.3 | 55 |
| 209 | Understanding microRNAs in neurodegeneration. Nature Reviews Neuroscience, 2009, 10, 837-841. | 4.9 | 256 |
| 210 | Calpain activation is not required for AIF translocation in PARPâ€1â€dependent cell death (parthanatos). Journal of Neurochemistry, 2009, 110, 687-696. | 2.1 | 89 |
| 211 | Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine). Journal of Neuroscience, 2009, 29, 15846-15850. | 1.7 | 114 |
| 212 | Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos. Experimental Neurology, 2009, 218, 193-202. | 2.0 | 327 |
| 213 | SnapShot: Pathogenesis of Parkinson's Disease. Cell, 2009, 139, 440.e1-440.e2. | 13.5 | 12 |
| 214 | Revelations and revolutions in the understanding of Parkinsonâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 585-586. | 1.8 | 3 |
| 215 | Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With Î±-Synuclein Inclusions. Journal of Neuropathology and Experimental Neurology, 2009, 68, 785-796. | 0.9 | 29 |
| 216 | Abnormal Localization of Leucine-Rich Repeat Kinase 2 to the Endosomal-Lysosomal Compartment in Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 994-1005. | 0.9 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Role of Tuberin in Neuronal Degeneration. Neurochemical Research, 2008, 33, 1113-1116. | 1.6 | 10 |
| 218 | Value of genetic models in understanding the cause and mechanisms of Parkinsonâ€™s disease. Current Neurology and Neuroscience Reports, 2008, 8, 288-296. | 2.0 | 41 |
| 219 | Morphometry of the human substantia nigra in ageing and Parkinsonâ€™s disease. Acta Neuropathologica, 2008, 115, 461-470. | 3.9 | 150 |
| 220 | Mitochondrial and Nuclear Cross Talk in Cell Death. Annals of the New York Academy of Sciences, 2008, 1147, 233-241. | 1.8 | 284 |
| 221 | Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nature Cell Biology, 2008, 10, 866-873. | 4.6 | 353 |
| 222 | Parkin mediates the degradationâ€independent ubiquitination of Hsp70. Journal of Neurochemistry, 2008, 105, 1806-1819. | 2.1 | 101 |
| 223 | Non-autonomous cell death in Parkinson's disease. Lancet Neurology, The, 2008, 7, 474-475. | 4.9 | 16 |
| 224 | Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Human Molecular Genetics, 2008, 17, 2570-2582. | 1.4 | 143 |
| 225 | Advances in Neuronal Cell Death 2007. Stroke, 2008, 39, 286-288. | 1.0 | 36 |
| 226 | Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. Autophagy, 2008, 4, 251-253. | 4.3 | 54 |
| 227 | The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2. Journal of Neuroscience, 2008, 28, 3384-3391. | 1.7 | 178 |
| 228 | Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Research, 2008, 36, 6959-6976. | 6.5 | 359 |
| 229 | Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Human Molecular Genetics, 2008, 17, 431-439. | 1.4 | 379 |
| 230 | Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents. Journal of Biological Chemistry, 2007, 282, 16441-16453. | 1.6 | 225 |
| 231 | The Roles of Kinases in Familial Parkinson's Disease. Journal of Neuroscience, 2007, 27, 11865-11868. | 1.7 | 51 |
| 232 | DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14807-14812. | 3.3 | 435 |
| 233 | Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced Solubility Alterations. Journal of Biological Chemistry, 2007, 282, 12310-12318. | 1.6 | 75 |
| 234 | Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics, 2007, 16, 223-232. | 1.4 | 535 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Parkinson's disease genetic mutations increase cell susceptibility to stress: Mutant Î±-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiology of Aging, 2007, 28, 1709-1717. | 1.5 | 53 |
| 236 | A Hierarchical NGF Signaling Cascade Controls Ret-Dependent and Ret-Independent Events during Development of Nonpeptidergic DRG Neurons. Neuron, 2007, 54, 739-754. | 3.8 | 225 |
| 237 | Unraveling the role of defective genes in Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S248-S249. | 1.1 | 10 |
| 238 | Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. Journal of Neurochemistry, 2007, 100, 368-381. | 2.1 | 101 |
| 239 | Localization of Parkinsonâ€™s disease-associated LRRK2 in normal and pathological human brain. Brain Research, 2007, 1155, 208-219. | 1.1 | 139 |
| 240 | MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiology of Disease, 2007, 26, 312-322. | 2.1 | 64 |
| 241 | A Nitric Oxide Signaling Pathway Controls CREB-Mediated Gene Expression in Neurons. Molecular Cell, 2006, 21, 283-294. | 4.5 | 211 |
| 242 | Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiology of Aging, 2006, 27, 524-529. | 1.5 | 130 |
| 243 | Parkin Blushed by PINK1. Neuron, 2006, 50, 527-529. | 3.8 | 39 |
| 244 | Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation, 2006, 116, 1744-1754. | 3.9 | 538 |
| 245 | Taming the clot-buster tPA. Nature Medicine, 2006, 12, 993-994. | 15.2 | 8 |
| 246 | Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience, 2006, 9, 1231-1233. | 7.1 | 587 |
| 247 | Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3887-3889. | 3.3 | 222 |
| 248 | Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18314-18319. | 3.3 | 655 |
| 249 | Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate. Journal of Biological Chemistry, 2006, 281, 16193-16196. | 1.6 | 91 |
| 250 | Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of Â-Synucleinopathy. Journal of Neuroscience, 2006, 26, 3685-3696. | 1.7 | 86 |
| 251 | Poly(ADP-ribose) (PAR) polymer is a death signal. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18308-18313. | 3.3 | 572 |
| 252 | Lessons from Drosophila Models of DJ-1 Deficiency. Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, pe2-pe2. | 0.9 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Failures and Successes of Clinical Trials for Parkinson Disease Treatments. Retina, 2005, 25, S75-S77. | 1.0 | 2 |
| 254 | Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. Journal of Neurochemistry, 2005, 93, 422-431. | 2.1 | 110 |
| 255 | Neurotoxicity and behavioral deficits associated with Septinâ€ƒ5 accumulation in dopaminergic neurons. Journal of Neurochemistry, 2005, 94, 1040-1053. | 2.1 | 65 |
| 256 | The involvement of nitric oxide in the enhanced expression of Î¼ -opioid receptors during intestinal inflammation in mice. British Journal of Pharmacology, 2005, 145, 758-766. | 2.7 | 29 |
| 257 | The role of nitric oxide and PARP in neuronal cell death. , 2005, , 146-156. | | 0 |
| 258 | Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Human Molecular Genetics, 2005, 14, 2571-2586. | 1.4 | 200 |
| 259 | Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Human Molecular Genetics, 2005, 14, 71-84. | 1.4 | 231 |
| 260 | Bcl-x Is Required for Proper Development of the Mouse Substantia Nigra. Journal of Neuroscience, 2005, 25, 6721-6728. | 1.7 | 140 |
| 261 | Sâ€Nitrosylation in Parkinson's Disease and Related Neurodegenerative Disorders. Methods in Enzymology, 2005, 396, 139-150. | 0.4 | 38 |
| 262 | Identification and Evaluation of NOâ€Regulated Genes by Differential Analysis of Primary cDNA Library Expression (DAzLE). Methods in Enzymology, 2005, 396, 359-368. | 0.4 | 1 |
| 263 | Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18676-18681. | 3.3 | 390 |
| 264 | Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation. Journal of Neuroscience, 2005, 25, 2002-2009. | 1.7 | 489 |
| 265 | Aggregation promoting C-terminal truncation of Â-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2162-2167. | 3.3 | 405 |
| 266 | Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death. Journal of Neuroscience, 2005, 25, 7968-7978. | 1.7 | 221 |
| 267 | The Road to Survival Goes through PARG. Cell Cycle, 2005, 4, 397-399. | 1.3 | 21 |
| 268 | Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Human Molecular Genetics, 2005, 14, 3885-3897. | 1.4 | 201 |
| 269 | Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Human Molecular Genetics, 2005, 14, 2063-2073. | 1.4 | 381 |
| 270 | Â-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells. Journal of Neuroscience, 2005, 25, 5544-5552. | 1.7 | 237 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE. Annual Review of Neuroscience, 2005, 28, 57-87. | 5.0 | 1,111 |
| 272 | From The Cover: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16842-16847. | 3.3 | 1,084 |
| 273 | Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Molecular Brain Research, 2005, 134, 103-108. | 2.5 | 71 |
| 274 | The 350-fold compacted Fugu parkin gene is structurally and functionally similar to human Parkin. Gene, 2005, 346, 97-104. | 1.0 | 6 |
| 275 | To die or grow: Parkinson's disease and cancer. Trends in Neurosciences, 2005, 28, 348-352. | 4.2 | 110 |
| 276 | AÎ² deposition is associated with enhanced cortical Î±-synuclein lesions in Lewy body diseases. Neurobiology of Aging, 2005, 26, 1183-1192. | 1.5 | 200 |
| 277 | Recent advances in our understanding of Parkinson's disease. Drug Discovery Today Disease Mechanisms, 2005, 2, 427-433. | 0.8 | 14 |
| 278 | Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacological Research, 2005, 52, 5-14. | 3.1 | 218 |
| 279 | Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Human Molecular Genetics, 2005, 14, 3801-3811. | 1.4 | 321 |
| 280 | Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17699-17704. | 3.3 | 285 |
| 281 | Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10744-10749. | 3.3 | 317 |
| 282 | Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 647-652. | 3.3 | 32 |
| 283 | Identification and analysis of plasticity-induced late-response genes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2145-2150. | 3.3 | 57 |
| 284 | PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. Journal of Neurochemistry, 2004, 90, 1068-1075. | 2.1 | 266 |
| 285 | Deadly Conversations: Nuclear-Mitochondrial Cross-Talk. Journal of Bioenergetics and Biomembranes, 2004, 36, 287-294. | 1.0 | 169 |
| 286 | Parkin-associated Parkinsonâ€™s disease. Cell and Tissue Research, 2004, 318, 175-184. | 1.5 | 126 |
| 287 | S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function. Science, 2004, 304, 1328-1331. | 6.0 | 736 |
| 288 | Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Annals of Medicine, 2004, 36, 315-320. | 1.5 | 123 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | P3-228 Chip and HSP70 regulate tau ubiquitination, degradation and aggregation. Neurobiology of Aging, 2004, 25, S419-S420. | 1.5 | 2 |
| 290 | Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death. Journal of Neuroscience, 2004, 24, 10963-10973. | 1.7 | 258 |
| 291 | Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends in Pharmacological Sciences, 2004, 25, 259-264. | 4.0 | 423 |
| 292 | Parkin and Hsp70 Sacked by BAG5. Neuron, 2004, 44, 899-901. | 3.8 | 23 |
| 293 | CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Human Molecular Genetics, 2004, 13, 703-714. | 1.4 | 613 |
| 294 | Astroglia Induce Cytotoxic Effects on Brain Tumors via a Nitric Oxide-Dependent Pathway Both in Vitro and in Vivo. Neurosurgery, 2004, 54, 1231-1238. | 0.6 | 13 |
| 295 | What have Genetically Engineered Mice Taught Us About Ischemic Injury?. Current Molecular Medicine, 2004, 4, 207-225. | 0.6 | 14 |
| 296 | Role for the Ubiquitin-Proteasome System in Parkinson's Disease and Other Neurodegenerative Brain Amyloidoses. NeuroMolecular Medicine, 2003, 4, 95-108. | 1.8 | 50 |
| 297 | Genetics of Parkinson's disease: What do mutations in DJ-1 tell us?. Annals of Neurology, 2003, 54, 281-282. | 2.8 | 14 |
| 298 | A missense mutation (L166P) in DJâ€1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homoâ€oligomerization. Journal of Neurochemistry, 2003, 87, 1558-1567. | 2.1 | 198 |
| 299 | Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiology of Disease, 2003, 14, 303-317. | 2.1 | 185 |
| 300 | Caught in the Act. Neuron, 2003, 40, 453-456. | 3.8 | 184 |
| 301 | BAK Alters Neuronal Excitability and Can Switch from Anti- to Pro-Death Function during Postnatal Development. Developmental Cell, 2003, 4, 575-585. | 3.1 | 101 |
| 302 | Molecular Pathways of Neurodegeneration in Parkinson's Disease. Science, 2003, 302, 819-822. | 6.0 | 1,530 |
| 303 | 37-kDa Laminin Receptor Precursor Modulates Cytotoxic Necrotizing Factor 1â€"mediated RhoA Activation and Bacterial Uptake. Journal of Biological Chemistry, 2003, 278, 16857-16862. | 1.6 | 106 |
| 304 | Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age. Journal of Biological Chemistry, 2003, 278, 48120-48128. | 1.6 | 140 |
| 305 | Nitric Oxide Protects Cardiac Sarcolemmal Membrane Enzyme Function and Ion Active Transport against Ischemia-induced Inactivation. Journal of Biological Chemistry, 2003, 278, 41798-41803. | 1.6 | 40 |
| 306 | Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. Journal of Biological Chemistry, 2003, 278, 13047-13055. | 1.6 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | The Cast of Molecular Characters in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 80-92. | 1.8 | 35 |
| 308 | Apoptosis Inducing Factor and PARPâ€Mediated Injury in the MPTP Mouse Model of Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 132-139. | 1.8 | 112 |
| 309 | Rare genetic mutations shed light on the pathogenesis of Parkinson disease. Journal of Clinical Investigation, 2003, 111, 145-151. | 3.9 | 91 |
| 310 | Rare genetic mutations shed light on the pathogenesis of Parkinson disease. Journal of Clinical Investigation, 2003, 111, 145-151. | 3.9 | 175 |
| 311 | Human Â-synuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with Â-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8968-8973. | 3.3 | 730 |
| 312 | The Orphan Nuclear Receptor, Steroidogenic Factor 1, Regulates Neuronal Nitric Oxide Synthase Gene Expression in Pituitary Gonadotropes. Molecular Endocrinology, 2002, 16, 2828-2839. | 3.7 | 27 |
| 313 | Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. Journal of Cell Biology, 2002, 158, 507-517. | 2.3 | 434 |
| 314 | Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor. Science, 2002, 297, 259-263. | 6.0 | 1,671 |
| 315 | Preconditioning-mediated neuroprotection through erythropoietin?. Lancet, The, 2002, 359, 96-97. | 6.3 | 54 |
| 316 | Lack of nitric oxide synthase depresses ion transporting enzyme function in cardiac muscle. Biochemical and Biophysical Research Communications, 2002, 294, 1030-1035. | 1.0 | 35 |
| 317 | Animal Models of PD. Neuron, 2002, 35, 219-222. | 3.8 | 131 |
| 318 | Mechanisms of ischemic tolerance. , 2002, , 58-71. |  | 0 |
| 319 | Poly(ADP-Ribose) Polymerase Impairs Early and Long-Term Experimental Stroke Recovery. Stroke, 2002, 33, 1101-1106. | 1.0 | 123 |
| 320 | The genetics of Parkinsonâ€™s disease. Current Neurology and Neuroscience Reports, 2002, 2, 439-446. | 2.0 | 27 |
| 321 | A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. Journal of Neurochemistry, 2002, 83, 186-192. | 2.1 | 75 |
| 322 | CREB family transcription factors inhibit neuronal suicide. Nature Medicine, 2002, 8, 450-451. | 15.2 | 51 |
| 323 | Neuroprotective and neurorestorative strategies for Parkinson's disease. Nature Neuroscience, 2002, 5, 1058-1061. | 7.1 | 152 |
| 324 | Gene therapy to the rescue in Parkinson's disease. Trends in Pharmacological Sciences, 2001, 22, 103-105. | 4.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends in Neurosciences, 2001, 24, 7-14. | 4.2 | 161 |
| 326 | Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. Science, 2001, 291, 2423-2428. | 6.0 | 1,035 |
| 327 | Reduction of functional N-methyl-d-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. Journal of Neurochemistry, 2001, 76, 1386-1394. | 2.1 | 8 |
| 328 | Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. European Journal of Neuroscience, 2001, 13, 1683-1693. | 1.2 | 87 |
| 329 | Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Annals of Neurology, 2001, 50, 6-16. | 2.8 | 85 |
| 330 | Parkin ubiquitinates the Î±-synucleinâ€"interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Medicine, 2001, 7, 1144-1150. | 15.2 | 710 |
| 331 | Parkin: clinical aspects and neurobiology. Clinical Neuroscience Research, 2001, 1, 467-482. | 0.8 | 15 |
| 332 | Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics, 2001, 10, 919-926. | 1.4 | 442 |
| 333 | NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase. Journal of Neuroscience, 2000, 20, 8005-8011. | 1.7 | 206 |
| 334 | Stroke Outcome in Double-Mutant Antioxidant Transgenic Mice. Stroke, 2000, 31, 2685-2691. | 1.0 | 44 |
| 335 | Parkinson's disease: clinical manifestations and treatment. International Review of Psychiatry, 2000, 12, 263-269. | 1.4 | 5 |
| 336 | Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease. Neurobiology of Disease, 2000, 7, 240-250. | 2.1 | 397 |
| 337 | Reply: a new look at the pathogenesis of Parkinsonâ€™s disease. Trends in Pharmacological Sciences, 2000, 21, 165. | 4.0 | 22 |
| 338 | Neuronal ischaemic preconditioning. Trends in Pharmacological Sciences, 2000, 21, 423-424. | 4.0 | 55 |
| 339 | New Animal Models for Parkinson's Disease. Cell, 2000, 101, 115-118. | 13.5 | 92 |
| 340 | Mechanisms and Structural Determinants of HIV-1 Coat Protein, gp41-Induced Neurotoxicity. Journal of Neuroscience, 1999, 19, 64-71. | 1.7 | 71 |
| 341 | Circadian Locomotor Analysis of Male Mice Lacking the Gene for Neuronal Nitric Oxide Synthase (nNOSâ€"/â€"). Journal of Biological Rhythms, 1999, 14, 20-27. | 1.4 | 29 |
| 342 | Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine, 1999, 5, 1403-1409. | 15.2 | 1,007 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 343 | Synphilin-1 associates with Î±-synuclein and promotes the formation of cytosolic inclusions. Nature Genetics, 1999, 22, 110-114. | 9.4 | 473 |
| 344 | Overview of the Pathway and Functions of Nitric Oxide. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al ], 1999, 00, Unit 10.1. | 1.1 | 0 |
| 345 | Nuclear Targeting of Mutant Huntingtin Increases Toxicity. Molecular and Cellular Neurosciences, 1999, 14, 121-128. | 1.0 | 177 |
| 346 | Histochemical Analysis of Nitric Oxide Synthase by NADPH Diaphorase Staining. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al ], 1999, 1, Unit 10.6. | 1.1 | 7 |
| 347 | Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats. Stroke, 1999, 30, 1279-1285. | 1.0 | 56 |
| 348 | Free Radicals as Mediators of Neuronal Injury. Cellular and Molecular Neurobiology, 1998, 18, 667-682. | 1.7 | 208 |
| 349 | Chapter 1 Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Progress in Brain Research, 1998, 118, 3-11. | 0.9 | 110 |
| 350 | Chapter 15 Nitric oxide in neurodegeneration. Progress in Brain Research, 1998, 118, 215-229. | 0.9 | 336 |
| 351 | Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems. Neuroscientist, 1998, 4, 96-112. | 2.6 | 20 |
| 352 | NMDAR1 Glutamate Receptor Subunit Isoforms in Neostriatal, Neocortical, and Hippocampal Nitric Oxide Synthase Neurons. Journal of Neuroscience, 1998, 18, 1725-1734. | 1.7 | 71 |
| 353 | Manganese Superoxide Dismutase Protects nNOS Neurons from NMDA and Nitric Oxide-Mediated Neurotoxicity. Journal of Neuroscience, 1998, 18, 2040-2055. | 1.7 | 258 |
| 354 | Differential Susceptibility to Neurotoxicity Mediated by Neurotrophins and Neuronal Nitric Oxide Synthase. Journal of Neuroscience, 1997, 17, 4633-4641. | 1.7 | 98 |
| 355 | Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Medicine, 1997, 3, 421-428. | 15.2 | 346 |
| 356 | Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nature Medicine, 1997, 3, 571-574. | 15.2 | 138 |
| 357 | Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Medicine, 1997, 3, 1089-1095. | 15.2 | 1,002 |
| 358 | NMDA-R1 subunit of the cerebral cortex co-localizes with neuronal nitric oxide synthase at pre- and postsynaptic sites and in spines. Brain Research, 1997, 750, 25-40. | 1.1 | 102 |
| 359 | Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone. Brain Research, 1997, 769, 66-70. | 1.1 | 62 |
| 360 | Effects of Nitric Oxide on Neuroendocrine Function and Behavior. Frontiers in Neuroendocrinology, 1997, 18, 463-491. | 2.5 | 107 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Nitric Oxide Synthase in Models of Focal Ischemia. Stroke, 1997, 28, 1283-1288. | 1.0 | 578 |
| 362 | NITRIC OXIDE SYNTHASE: Role as a Transmitter/Mediator in the Brain and Endocrine System. Annual Review of Medicine, 1996, 47, 219-227. | 5.0 | 141 |
| 363 | Nitric oxide neurotoxicity. Journal of Chemical Neuroanatomy, 1996, 10, 179-190. | 1.0 | 460 |
| 364 | NITRIC OXIDE ACTIONS IN NEUROCHEMISTRY. Neurochemistry International, 1996, 29, 97-110. | 1.9 | 174 |
| 365 | Nitric Oxide Synthase Inhibitors. CNS Drugs, 1996, 6, 351-357. | 2.7 | 10 |
| 366 | Generation of isoform-specific antibodies to nitric oxide synthases. Methods in Enzymology, 1996, 268, 349-358. | 0.4 | 4 |
| 367 | Nitric oxide synthase (NOS) in schizophrenia. Molecular and Chemical Neuropathology, 1996, 27, 275-284. | 1.0 | 71 |
| 368 | Immunosuppressants, immunophilins, and the nervous system. Annals of Neurology, 1996, 40, 559-560. | 2.8 | 31 |
| 369 | Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. Journal of Neurosurgery, 1996, 84, 648-654. | 0.9 | 138 |
| 370 | Neurobiology of Nitric Oxide. Critical Reviews in Neurobiology, 1996, 10, 291-316. | 3.3 | 255 |
| 371 | Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Annals of Neurology, 1995, 37, 115-118. | 2.8 | 68 |
| 372 | Effects of Central Inhibition of Nitric Oxide Synthase on Focal Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 779-786. | 2.4 | 34 |
| 373 | Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature, 1995, 378, 383-386. | 13.7 | 606 |
| 374 | REVIEW â– : Nitric Oxide: Actions and Pathological Roles. Neuroscientist, 1995, 1, 7-18. | 2.6 | 100 |
| 375 | Physiological and Toxicological Actions of Nitric Oxide in the Central Nervous System. Advances in Pharmacology, 1995, 34, 323-342. | 1.2 | 62 |
| 376 | Widespread expression of Huntington's disease gene (IT15) protein product. Neuron, 1995, 14, 1065-1074. | 3.8 | 485 |
| 377 | Chapter 30 Nitric oxide: cellular regulation and neuronal injury. Progress in Brain Research, 1994, 103, 365-369. | 0.9 | 72 |
| 378 | Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Annals of Neurology, 1994, 36, 778-786. | 2.8 | 527 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Nitric oxide mediates the formation of synaptic connections in developing and regenerating olfactory receptor neurons. Neuron, 1994, 13, 289-299. | 3.8 | 232 |
| 380 | gp120 neurotoxicity in primary cortical cultures. Advances in Neuroimmunology, 1994, 4, 167-173. | 1.8 | 24 |
| 381 | Secondary mechanisms in neuronal trauma. Current Opinion in Neurology, 1994, 7, 510-516. | 1.8 | 141 |
| 382 | Molecular Mechanisms of Nitric Oxide Actions in the Brain<sup>a</sup>. Annals of the New York Academy of Sciences, 1994, 738, 76-85. | 1.8 | 103 |
| 383 | Reactive nitrogen intermediates: Effector molecules of immune-mediated inflammatory nervous system disorders?. Annals of Neurology, 1993, 33, 422-422. | 2.8 | 0 |
| 384 | Possible Origins and Distribution of Immunoreactive Nitric Oxide Synthase-Containing Nerve Fibers in Cerebral Arteries. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 70-79. | 2.4 | 370 |
| 385 | Neurotransmitter release regulated by nitric oxide in PC-12 cells and brain synaptosomes. Current Biology, 1993, 3, 749-754. | 1.8 | 108 |
| 386 | Enhanced expression of nitric oxide synthase by rat retina following pterygopalatine parasympathetic denervation. Brain Research, 1993, 631, 83-88. | 1.1 | 48 |
| 387 | Targeted disruption of the neuronal nitric oxide synthase gene. Cell, 1993, 75, 1273-1286. | 13.5 | 1,323 |
| 388 | High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature, 1992, 358, 584-587. | 13.7 | 338 |
| 389 | Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. Annals of Neurology, 1992, 32, 818-820. | 2.8 | 177 |
| 390 | Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants. Brain Research, 1991, 540, 145-152. | 1.1 | 22 |
| 391 | Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron, 1991, 7, 615-624. | 3.8 | 1,390 |
| 392 | Thrombotic microangiopathy isolated to the central nervous system. Annals of Neurology, 1991, 30, 843-846. | 2.8 | 2 |
| 393 | Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. Brain Research Bulletin, 1990, 25, 903-912. | 1.4 | 36 |
| 394 | Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology, 1988, 94, 141-143. | 1.5 | 61 |
| 395 | Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. Life Sciences, 1988, 42, 1933-1939. | 2.0 | 77 |
| 396 | Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase. Brain Research Bulletin, 1988, 20, 447-459. | 1.4 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Presynaptic and postsynaptic D1 dopamine receptors in the nigrostriatal system of the rat brain: a quantitative autoradiographic study using the selective D1 antagonist [3H]SCH 23390. Brain Research, 1987, 408, 205-209. | 1.1 | 84 |
| 398 | Chronic administration of sertraline, a selective serotonin uptake inhibitor, decreased the density of Î²-adrenergic receptors in rat frontoparietal cortex. Brain Research, 1987, 421, 377-381. | 1.1 | 29 |
| 399 | Evidence that [3H]forskolin binding in the substantia nigra is intrinsic to a striatal-nigral projection: An autoradiographic study of rat brain. Neuroscience Letters, 1987, 73, 114-118. | 1.0 | 27 |
| 400 | Autoradiographic Evidence of [3H]SCH 23390 Binding Site; in Human Prefrontal Cortex (Brodmann's) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 2.1 | 34 |
| 401 | Quantitative autoradiographic evidence for axonal transport of imipramine receptors in the central nervous system of the rat. Neuroscience Letters, 1985, 55, 261-266. | 1.0 | 32 |